Susquehanna International Group’s BiondVax Pharmaceuticals Ltd. BVXVW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-12,590
| Closed | -$5K | – | 11458 |
|
|
2020
Q1 | $5K | Sell |
12,590
-8,641
| -41% | -$24.5K | ﹤0.01% | 10113 |
|
|
2019
Q4 | $55K | Sell |
21,231
-1,483
| -7% | -$1.97K | ﹤0.01% | 9326 |
|
|
2019
Q3 | $14K | Buy |
22,714
+2,252
| +11% | +$2.21K | ﹤0.01% | 9989 |
|
|
2019
Q2 | $15K | Sell |
20,462
-500
| -2% | -$541 | ﹤0.01% | 10038 |
|
|
2019
Q1 | $7K | Sell |
20,962
-400
| -2% | -$224 | ﹤0.01% | 8670 |
|
|
2018
Q4 | $9K | Sell |
21,362
-500
| -2% | -$481 | ﹤0.01% | 8757 |
|
|
2018
Q3 | $26K | Buy |
21,862
+5,500
| +34% | +$6.86K | ﹤0.01% | 8971 |
|
|
2018
Q2 | $21K | Buy |
+16,362
| New | +$21.3K | ﹤0.01% | 9423 |
|
|
2018
Q1 | – | Sell |
-72,800
| Closed | -$106K | – | 10605 |
|
|
2017
Q4 | $106K | Hold |
72,800
| – | – | ﹤0.01% | 8665 |
|
|
2017
Q3 | $127K | Hold |
72,800
| – | – | ﹤0.01% | 8273 |
|
|
2017
Q2 | $187K | Hold |
72,800
| – | – | ﹤0.01% | 8347 |
|
|
2017
Q1 | $107K | Hold |
72,800
| – | – | ﹤0.01% | 8360 |
|
|
2016
Q4 | $27K | Buy |
+72,800
| New | +$29.1K | ﹤0.01% | 9393 |
|
Susquehanna International Group's BVXVW Position: Q2 2020 in Review
Susquehanna International Group sold out of BiondVax Pharmaceuticals Ltd. (BVXVW) in Q2 2020, closing a stake of 12,590 shares — an estimated $5K sold.
Susquehanna International Group first reported a position in BVXVW in Q4 2016 and held it in 13 quarters. The position peaked at $187K in Q2 2017. 0 funds tracked by Wall St. Rank hold BVXVW as of Q2 2020.
- Susquehanna International Group reported no remaining BiondVax Pharmaceuticals Ltd. position as of Q2 2020 after selling out during the quarter.
- Susquehanna International Group sold 12,590 BiondVax Pharmaceuticals Ltd. shares in Q2 2020, an estimated $5K.
- Susquehanna International Group first reported a position in BiondVax Pharmaceuticals Ltd. in Q4 2016 and held it in 13 quarters.
- Susquehanna International Group's BiondVax Pharmaceuticals Ltd. position peaked at $187K in Q2 2017.
- 0 funds tracked by Wall St. Rank held BiondVax Pharmaceuticals Ltd. as of Q2 2020.
Based on Susquehanna International Group's 13F filing for Q2 2020, filed 14 Aug 2020.